On Jan 15, Pfizer Inc. (PFE, Financial) announced to sale of about 700 million ordinary shares of Haleon plc through a secondary offering. The sale is 7.7% of Haleon's issued share capital and will be undertaken following an accelerated book-building process dealing with institutional investors.
Proceeding at speed, the book-building period opened straight away after the announcement, with the details and pricing of when it ends still to come. Once complete, Pfizer's stake in Haleon will fall from 15.0% to around 7.3%.
Pfizer's move comes after Haleon's spin-off as an independent consumer healthcare company, part of plans to reshape its portfolio. This transaction will not result in any proceeds to Haleon, which will not resume the issue of new shares or participate in the offering. Any money raised will go straight to Pfizer.
As lead managers on the offering, joint global coordinators and bookrunners are J.P. Morgan and Morgan Stanley. HSBC, BNP PARIBAS, Mizuho, and UBS are additional joint bookrunners, as are co-managers BofA Securities, Deutsche Numis, Goldman Sachs International and Loop Capital Markets.
Under this settlement, Pfizer has entered into a 60-day lock-up from the date of the settlement with the sale of Haleon shares, preventing further trading in the Haleon shares subject to this lock-up agreement within 60 days unless as permitted by the joint global coordinators under specific conditions or waivers.
That sale, which does not include American depositary shares, is subject to normal closing conditions. Pfizer said the announcement does not indicate a public offering or solicitation for the sale of the shares.
This article first appeared on GuruFocus.免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。